Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2025-12-27 @ 7:32 AM
Study NCT ID:
NCT00060567
Status:
COMPLETED
Last Update Posted:
2023-06-18
First Post:
2003-05-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose-Finding Study of E7070 in Combination With Irinotecan
Sponsor:
Eisai Inc.
Organization:
Study Overview
Official Title:
Phase I Dose-Finding Study of E7070 in Combination With Irinotecan
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: